鄧小鹿, 彭 鏡, 何 芳, 楊麗芬, 吳麗文, 尹 飛
(中南大學(xué)湘雅醫(yī)院兒科,湖南長(zhǎng)沙410008)
腫瘤壞死因子 α(tumor necrosis factor α,TNF - α)主要由單核細(xì)胞和巨細(xì)胞產(chǎn)生,在介導(dǎo)中樞神經(jīng)系統(tǒng)感染的炎癥過(guò)程中起著重要作用。本實(shí)驗(yàn)室前期研究證實(shí),感染性腦水腫大鼠腦組織的TNF-α含量明顯增高,與腦水腫的嚴(yán)重程度呈正相關(guān)[1];Rho激酶抑制劑Y-27632可以減輕TNF-α導(dǎo)致的腦微血管內(nèi)皮細(xì)胞通透性增高[2]。同時(shí),已有研究顯示RhoA/Rho激酶信號(hào)通路是調(diào)控內(nèi)皮細(xì)胞屏障功能的重要環(huán)節(jié),其中RhoA的活性由Rho鳥(niǎo)嘌呤核苷酸交換因子(Rho guanine nucleotide exchange factors, RhoGEFs)催 化。p115RhoGEF是第一個(gè)被發(fā)現(xiàn)聯(lián)系G蛋白偶聯(lián)受體和Rho家族的RhoGEFs,介導(dǎo)多種刺激因素如凝血酶、溶血凝脂酸、血栓素-2對(duì)RhoA的活化[3]。因此,我們認(rèn)為p115RhoGEF可能也參與了TNF-α對(duì)RhoA的調(diào)控,而目前未見(jiàn)相關(guān)文獻(xiàn)報(bào)道。本研究檢測(cè)了TNF-α刺激小鼠腦微血管內(nèi)皮細(xì)胞不同時(shí)點(diǎn)RhoA活性和蛋白表達(dá)水平,并通過(guò)siRNA抑制p115RhoGEF表達(dá),探討其在TNF-α對(duì)RhoA活性調(diào)控中的作用。
小鼠腦微血管內(nèi)皮細(xì)胞株bEnd.3由美國(guó)芝加哥大學(xué)章堅(jiān)教授饋贈(zèng),RhoA活性檢測(cè)試劑盒購(gòu)自Cytoskeleton,DMEM高糖培養(yǎng)基購(gòu)自Thermo,胎牛血清(fetal bovine serum,F(xiàn)BS)購(gòu)自杭州四季青公司,重組人TNF-α購(gòu)自Sigma,兔抗RhoA單克隆抗體購(gòu)自CST,山羊抗p115RhoGEF多克隆抗體和HRP標(biāo)記的羊抗兔IgG購(gòu)自Santa Cruz,p115RhoGEF siRNA由上海吉?jiǎng)P基因技術(shù)有限公司合成。其余生化試劑為國(guó)產(chǎn)分析純?cè)噭┗蜻M(jìn)口分裝。
2.1 細(xì)胞培養(yǎng) 應(yīng)用 DMEM(含 10%FBS)培養(yǎng)液,在37℃、5%CO2培養(yǎng)箱條件下培養(yǎng)bEnd.3細(xì)胞,每3 d按1∶2的比例傳代,每日于倒置相差顯微鏡下觀察細(xì)胞形態(tài)與生長(zhǎng)狀態(tài),1-2 d更換1次培養(yǎng)液。
2.2 siRNA轉(zhuǎn)染 參考文獻(xiàn)[4]合成p115RhoGEF siRNA。合成引物序列如下:正義鏈5'-CAUACCAUCUCUACCGACGtt-3';反義鏈5'-CGUCGGUAGAGAUGGUAUGtt-3'。采用 Invitrogen公司的Lipofectamine 2000將p115RhoGEF siRNA轉(zhuǎn)染bEnd.3細(xì)胞,無(wú)活性的nsRNA作為對(duì)照。轉(zhuǎn)染72 h后,利用Western blotting驗(yàn)證siRNA抑制p115RhoGEF蛋白合成的效果。
2.3 RhoA活性和表達(dá)分析及分組 將bEnd.3細(xì)胞分為正常對(duì)照組和TNF-α刺激組。去血清培養(yǎng)24 h,加入TNF-α(10 μg/L)刺激,在 10、30、60 min 利用 pull- down 法檢測(cè)RhoA活性,得到TNF-α作用與RhoA活化的時(shí)效關(guān)系。取RhoA活化最明顯的時(shí)點(diǎn),bEnd.3細(xì)胞轉(zhuǎn)染p115RhoGEF siRNA和nsRNA,檢測(cè)TNF-α刺激后RhoA的活性變化。Pull-down法操作步驟依照Cytoskeleton提供的RhoA活性測(cè)定試劑盒說(shuō)明書進(jìn)行。Western blotting檢測(cè)RhoA-GTP的表達(dá),RhoA-GTP/總RhoA的比值代表RhoA活性。
將bEnd.3細(xì)胞分為正常對(duì)照組和TNF-α刺激組。去血清培養(yǎng)24h,分為1、3、6、12、24 h 組,加入 TNF - α(10 μg/L)進(jìn)行預(yù)處理后收集各組總蛋白,Western blotting檢測(cè)RhoA蛋白表達(dá)變化。
2.4 Western blotting 每孔加樣品總蛋白量30 μg行SDSPAGE電泳分離及轉(zhuǎn)膜,Ⅰ抗工作效價(jià)為1∶500,ECL化學(xué)發(fā)光法顯影,Quantity One圖像分析系統(tǒng)進(jìn)行顯影條帶灰度值分析。
與對(duì)照組相比,bEnd.3細(xì)胞RhoA活性在TNF-α處理10 min無(wú)明顯變化;30 min明顯增高達(dá)到高峰(P<0.01),60 min稍下降但仍高于對(duì)照組(P<0.05),見(jiàn)圖1。
Figure 1.Activation of RhoA by TNF-α.The bEnd.3 cells were incubated in the presence of TNF - α (10 μg/L)for the indicated time.A:RhoA activation was determined by pull-down assay.The RhoA -GTP pulled down from lysates was detected by Western blotting using a specific anti-RhoA antibody.The total amount of RhoA in cell lysates was used as a control for the comparison of RhoA activity.B:quantitation of pulldown experiments.±s.n=3.*P<0.05.**P<0.01 vs control.圖1 Pull-down檢測(cè)TNF-α對(duì)bEnd.3細(xì)胞RhoA活性的影響
RhoA總蛋白表達(dá)在TNF-α刺激12和24h上調(diào),與對(duì)照組之間的差異顯著(P<0.05),見(jiàn)圖2。
Figure 2.Time-course changes in the upregulation of RhoA protein induced by TNF - α (10 μg/L).The bEnd.3 cells were incubated in the presence of TNF-α(10 μg/L)for the indicated time points.A:total proteins were assayed for RhoA by Western blotting.The β -actin in cell lysates was used as a control.B:the expression levels of RhoA were summarized.±s.n=3.*P <0.05 vs control.圖2 TNF-α對(duì)bEnd.3細(xì)胞RhoA蛋白表達(dá)量的影響
與對(duì)照組相比,轉(zhuǎn)染 p115RhoGEF siRNA的細(xì)胞p115RhoGEF的表達(dá)明顯減少(P<0.01),分析顯示其蛋白條帶灰度值較對(duì)照組降低約91%,見(jiàn)圖3。
Figure 3.Suppression of endogenous p115RhoGEF protein by siRNA.A:the bEnd.3 cells were transiently transfected with active siRNA against p115RhoGEF(siRNA)or the non-silencing RNA(nsRNA)and the protein lysates prepared at 72 h.Total proteins were assayed for p115RhoGEF by Western blotting.The β- actin in cell lysates was used as a control.B:the expression levels of p115RhoGEF were summarized.±s.n=3.**P <0.01 vs nsRNA.圖3 siRNA對(duì)p115RhoGEF蛋白表達(dá)的影響
TNF-α作用30 min后p115RhoGEF siRNA組RhoA有部分活化,但較對(duì)照組明顯降低(P<0.05),分析顯示其蛋白條帶灰度值較對(duì)照組降低約51%,見(jiàn)圖4。
Figure 4.Effect of p115RhoGEF siRNA on TNF-α stimulated RhoA activation.A:p115RhoGEF siRNA or nsRNA were transfected into bEnd.3 cells and TNF - α -stimulated RhoA activation was measured by pulldown assay;B:quantitation of pull-down experiments.±s.n=3.*P<0.05 vs nsRNA.圖4 p115RhoGEF siRNA對(duì)TNF-α刺激后RhoA活性改變的影響
TNF-α是介導(dǎo)炎癥、感染和其它內(nèi)環(huán)境改變的重要起始因子,可直接損傷內(nèi)皮細(xì)胞,導(dǎo)致應(yīng)力纖維形成和細(xì)胞收縮。小G蛋白的Rho家族,由Rho、Rac和Cdc42三個(gè)亞家族組成,是一類能結(jié)合GTP的蛋白質(zhì),并能通過(guò)其下游效應(yīng)蛋白介導(dǎo)多種生物功能包括細(xì)胞骨架形成、黏附、增殖和轉(zhuǎn)錄。近年研究表明,多種炎癥介質(zhì)和細(xì)胞因子均能激活Rho/Rho激酶途徑,使肌球蛋白輕鏈磷酸化、肌動(dòng)-肌球蛋白交聯(lián)增加、F-actin骨架重組和應(yīng)力纖維生成,導(dǎo)致內(nèi)皮細(xì)胞收縮[5];Rho激酶抑制劑Y-27632可以抑制腫瘤細(xì)胞游走過(guò)程中引起的血管內(nèi)皮單細(xì)胞層電阻下降[6]。為探討TNF-α對(duì)腦微血管內(nèi)皮細(xì)胞RhoA的調(diào)控,本實(shí)驗(yàn)觀察了TNF-α處理bEn.d3細(xì)胞后RhoA的活性和表達(dá)變化,證實(shí)TNF-α(10 μg/L)誘導(dǎo)RhoA活性增高,RhoA-GTP表達(dá)在刺激后30min和60min明顯增加,30min達(dá)到高峰,同時(shí),總RhoA蛋白在TNF-α刺激后12 h和24 h上調(diào),與在支氣管平滑肌細(xì)胞的研究結(jié)果一致[7]。我們的結(jié)果表明RhoA參與了TNF-α介導(dǎo)腦微血管內(nèi)皮細(xì)胞內(nèi)信號(hào)傳遞過(guò)程,RhoA的活性和表達(dá)增加可能是TNF-α損傷內(nèi)皮細(xì)胞屏障功能的機(jī)制之一。
然而,TNF-α激活RhoA的具體機(jī)制仍不明確。RhoA的活化依賴GEFs催化GDP向GTP轉(zhuǎn)化,說(shuō)明GEFs在RhoA活化的信號(hào)轉(zhuǎn)導(dǎo)中發(fā)揮關(guān)鍵作用。p115RhoGEF是1996年由Hart等[8]發(fā)現(xiàn)的特異活化RhoA的GEF;G蛋白α亞單位12/13(Gα12/13)轉(zhuǎn)導(dǎo)激動(dòng)劑(如凝血酶和溶血凝脂酸)的信號(hào),通過(guò)提高p115RhoGEF的GEF活性來(lái)激活RhoA。同時(shí),Holinstat等[9]在外周血管內(nèi)皮細(xì)胞的研究中,發(fā)現(xiàn)凝血酶誘導(dǎo)的RhoA活化和隨之的細(xì)胞骨架重組需要Gα12/13與蛋白激酶Cα(PKCα)共同對(duì)p115RhoGEF的激活。上述研究提示p115RhoGEF參與了外界刺激對(duì)RhoA活化的調(diào)控,而TNF-α活化RhoA是否受p115RhoGEF調(diào)控尚未見(jiàn)報(bào)道。我們使用RNA干擾技術(shù)成功抑制了p115RhoGEF表達(dá),在此基礎(chǔ)上予TNF-α刺激,30 min后RhoA活化較對(duì)照組明顯降低,提示抑制p115RhoGEF可以部分阻止TNF-α對(duì)RhoA的激活,證實(shí)p115RhoGEF參與了TNF-α對(duì)RhoA活化的調(diào)控。
綜上所述,TNF-α可以誘導(dǎo)小鼠腦微血管內(nèi)皮細(xì)胞RhoA活性增加和表達(dá)上調(diào),在一定程度上揭示了TNF-α損傷內(nèi)皮細(xì)胞的機(jī)制。
[1]尹 飛,楊于嘉,虞佩蘭,等.大鼠百日咳菌液腦水腫腦組織腫瘤壞死因子-α變化[J].中國(guó)當(dāng)代兒科雜志,2000,2(2):82-85.
[2]彭 鏡,尹 飛,曾衛(wèi)民,等.腫瘤壞死因子對(duì)體外血腦屏障模型通透性的影響[J].中國(guó)組織工程研究與臨床康復(fù),2007,11(36):7286 -7289.
[3]Harenberg A,Girkontaite I,Giehl K,et al.The Lsc Rho-GEF mediates signaling from thromboxane A2to actin polymerization and apoptosis in thymocytes[J].Eur J Immunol,2005,35(6):1977 -1986.
[4]Wang Q,Liu M,Kozasa T,et al.Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells[J].J Biol Chem,2004,279(28):28831-28834.
[5]Wettschureck N,Offermanns S.Rho/Rho-kinase mediated signaling in physiology and pathophysiology[J].J Mol Med,2002,80(10):629-638.
[6]辛 華,鄭雅娟,韓振國(guó),等.內(nèi)皮細(xì)胞Rho及Rho激酶在肉瘤細(xì)胞向血管外游走過(guò)程中的作用[J].中國(guó)病理生理雜志,2004,20(6):950-953.
[7]Hunter I, Nixon GF. Spatial compartmentalization of tumor necrosis factor(TNF)receptor 1-dependent signaling pathways in human airway smooth muscle cells[J].J Biol Chem,2006,281(45):34705-34715.
[8]Hart MJ,Sharma S,elMasry N,et al.Identification of a novel guanine nucleotide exchange factor for the Rho GTPase[J].J Biol Chem,1996,271(41):25452 -25458.
[9]Holinstat M,Mehta D,Kozasa T,et al.Protein kinase Ca -induced p115RhoGEF phosphorylation signals endothelial cytoskeletal rearrangement[J].J Biol Chem,2003,278(31):28793-28798.